*Corresponding author:Pirogova I Yu, Doctor of Medicine, Associate Professor of the Department of Faculty Therapy of the State Educational Institution, South Ural State Medical University, Head of the Center for Gastroenterology and Hepatology, LLC Medical Center “Lotos”, Chelyabinsk, Russia, Tel: 89193395661; Email: firstname.lastname@example.org
Received: August 06, 2018; Published: August 09, 2018
To view the Full Article Peer-reviewed Article PDF
The aim of the study was to create a non-invasive model for diagnosing fibrosis and steatosis in non-alcoholic fatty liver disease. Materials and methods. The study included 183 patients with liver steatosis according to ultrasound of the liver. General clinical examination, verification of the stage of fibrosis and steatosis of the liver on the Fibroscan 502 TOUCH device with the CAP software was carried out. Results of the study. Fibrosteatotest ©, based on stigmas of inflammation activity, insulin resistance, lipid spectrum for the diagnosis of fibrosis and steatosis (diagnostic accuracy of more than 80% compared to the results of fibroscanning), is created by the method of discriminant analysis, which allows to identify patients with the 2nd and more stage of fibrosis and steatosis of the liver, who need medication.
Conclusions: The Fibrosteatotest © test allows for screening patients to identify the stages of fibrosis and steatosis of the liver that require drug therapy.
Keywords: Non-Alcoholic Fatty Liver Disease; Fibrosis and Steatosis of the Liver; Fibrosteatotest
We know the financial complexity of Individual read more...
The annual scholar awards from Lupine Publishers honor a selected number read more...